"KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), announces a manufacturing contract with Alanis Therapeutics, Inc. (ATI) for the development of an innovative pre-clinical therapeutic antibody to treat myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) blood cancers."